Not for release, publication or distribution, directly or indirectly, in or into United States, Canada, Australia, and Japan.

MDxHealth

MDxHealth's new share capital amount and number of shares

LIEGE, BELGIUM – July 2, 2013 – MDxHealth SA (NYSE Euronext : MDXH), in conformity with article 15 of the Law of May 2, 2007 on the publication of significant shareholdings in issuers which shares are admitted to trading on a regulated market, and further to the capital increase having taken place on Tuesday, June 25, 2013, MDxHealth publishes that its share capital has increased from EUR 20,351,568.70 to EUR 27,321,762.02 and that its issued and outstanding shares have increased from 25,513,440 to 34,251,303, through the issuance of 8,737,863 new shares.

About MDxHealth®

MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The company's first commercial product, ConfirmMDx™ for Prostate Cancer, has been shown to help distinguish patients who have a true-negative biopsy from those who may have undetected cancer. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for prostate, brain and lung cancers. The company is based in Irvine, California with a European headquarters in Liege, Belgium. For more information visit MDxHealth's website at www.mdxhealth.com.

For more information:

Dr. Jan Groen, CEO   Mike Sinclair
MDxHealth   Halsin Partners
US: +1 949 812 6979   UK: +44 20 7318 2955
BE: +32 4 364 20 70   Cell: +44 7968 022075
info@mdxhealth.com   msinclair@halsin.com

Important notice